| Project Information |
| Project Title: |
Metabolic test in vivo for malignant hyperthermia |
| Period: |
from: 2023-01-01
to: 2025-12-31
|
| Principal Investigator(s): |
Ibarra Moreno, Carlos Alberto
;
Pawliszyn, Janusz B
|
| Co-Investigators: |
Miles, Sarah
;
Tomlinson, George Andrew
|
| Supervisors: |
|
| Previous Investigators/Supervisors: |
|
| Institution: |
University Health Network (Toronto)
|
| Department: |
Anesthesiology and Pain Management |
| Agency: |
Canadian Institutes of Health Research |
| Program: |
Team Grant: E-Rare-3 Joint Transnational Call |
| Keywords: |
ANALYTICAL CHEMISTRY, BIOLOGIE MOLÉCULAIRE, DIAGNOSTIC BIOMARKERS, MALIGNANT HYPERTHERMIA, METABOLOMICS, MINIMALLY INVASIVE, MOLECULAR BIOLOGY, MULTIDISCIPLINAIRES, MULTIDISCIPLINARY, MUSCLE, BONE, OR JOINT, MUSCLES ET OS, MUSCLES, OS OU ARTICULATIONS, MUSCULO SKELETAL, SKELETAL MUSCLE, SOLID PHASE MICROEXTRACTION |
| Abstract: |
Malignant hyperthermia (MH) is a dangerous reaction to certain anesthetics, heat or exercise that can be fatal if left untreated, caused by an inherited dysregulation of calcium inside muscle cells. MH can be prevented by using alternative anesthetics in patients with suspected MH predisposition and in their relatives. At least half of the families affected by MH predisposition have no identifiable genetic marker and cannot benefit from genetic testing. To assess their risk of MH, a surgical muscle biopsy is required to evaluate their muscle response to drugs that may trigger MH by the so-called contracture tests, performed only by a few specialized centers globally. Many persons at risk refuse testing because of its invasiveness, cost, distance to the testing centre, risk of complications, and a painful convalescence. We envisage developing a test to diagnose MH using modified acupuncture needles applied into muscle. Needles for this "chemical biopsy" are coated with a sorbent designed to extract specific molecules (i.e., biomarkers) by a process called solid phase microextraction. A microinjection of caffeine into the muscle would trigger a local reaction only in patients predisposed to MH - but not in others, producing biomarkers that can be extracted and analyzed for diagnosis. Our consortium is a multidisciplinary team with the expertise to develop such a device and to test its diagnostic accuracy in a multicenter clinical trial. Developing a novel innocuous diagnostic tool for MH may translate into a considerable improvement in the identification of patients at risk.
|
| Funding Information |
| Fiscal
Year |
Amount |
| 2022-23 |
$37,434
|
|
